Literature DB >> 23983238

Viral hepatitis markers in liver tissue in relation to serostatus in hepatocellular carcinoma.

Brenda Y Hernandez1, Xuemei Zhu, Sandi Kwee, Owen T M Chan, Naoky Tsai, Gordon Okimoto, David Horio, Katherine A McGlynn, Sean Altekruse, Linda L Wong.   

Abstract

BACKGROUND: Hepatocellular carcinoma (HCC) incidence is increasing in the United States. Hepatitis B virus (HBV) and hepatitis C virus (HCV) are major causes of HCC. Hepatitis infection in patients with HCC is generally diagnosed by serology, which is not always consistent with the presence of HBV and HCV in the liver. The relationship of liver viral status to serostatus in hepatocarcinogenesis is not fully understood.
METHODS: HBV and HCV were evaluated in formalin-fixed, paraffin-embedded liver tissue specimens in a retrospective study of 61 U.S. HCC cases of known serologic status. HBV DNA and HCV RNA were detected by PCR, reverse transcription PCR (RT-PCR), and pyrosequencing, and HBsAg and HBcAg were evaluated by immunohistochemistry.
RESULTS: Viral markers were detected in the liver tissue of 25 of 61 (41%) HCC cases. Tissue viral and serologic status were discordant in 27 (44%) cases, including those with apparent "occult" infection. Specifically, HBV DNA was detected in tissue of 4 of 39 (10%) serum HBsAg (-) cases, including 1 anti-HCV(+) case; and HCV RNA was detected in tissue of 3 of 42 (7%) anti-HCV seronegative cases, including two with serologic evidence of HBV.
CONCLUSIONS: Viral hepatitis, including HBV-HCV coinfection, may be unrecognized in up to 17% of patients with HCC when based on serology alone. Further research is needed to understand the clinical significance of viral makers in liver tissue of patients with HCC in the absence of serologic indices. IMPACT: The contribution of HBV and HCV to the increasing incidence of HCC in the United States may be underestimated. ©2013 AACR.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23983238      PMCID: PMC3818344          DOI: 10.1158/1055-9965.EPI-13-0397

Source DB:  PubMed          Journal:  Cancer Epidemiol Biomarkers Prev        ISSN: 1055-9965            Impact factor:   4.254


  51 in total

1.  Characteristics of patients with chronic hepatitis C who develop hepatocellular carcinoma after a sustained response to interferon therapy.

Authors:  Akiko Makiyama; Yoshito Itoh; Akinori Kasahara; Yasuharu Imai; Sumio Kawata; Kentaro Yoshioka; Hirohito Tsubouchi; Kendo Kiyosawa; Shinichi Kakumu; Kiwamu Okita; Norio Hayashi; Takeshi Okanoue
Journal:  Cancer       Date:  2004-10-01       Impact factor: 6.860

Review 2.  Excess body weight and the risk of primary liver cancer: an updated meta-analysis of prospective studies.

Authors:  Yi Chen; Xiaolin Wang; Jianhua Wang; Zhiping Yan; Jianjun Luo
Journal:  Eur J Cancer       Date:  2012-03-23       Impact factor: 9.162

3.  Hepatitis C virus replicates in the liver of patients who have a sustained response to antiviral treatment.

Authors:  Inmaculada Castillo; Elena Rodríguez-Iñigo; Juan Manuel López-Alcorocho; Margarita Pardo; Javier Bartolomé; Vicente Carreño
Journal:  Clin Infect Dis       Date:  2006-10-05       Impact factor: 9.079

4.  Global cancer statistics, 2002.

Authors:  D Max Parkin; Freddie Bray; J Ferlay; Paola Pisani
Journal:  CA Cancer J Clin       Date:  2005 Mar-Apr       Impact factor: 508.702

5.  Occult hepatitis B infection and HBV replicative activity in patients with cryptogenic cause of hepatocellular carcinoma.

Authors:  Danny Ka Ho Wong; Fung Yu Huang; Ching Lung Lai; Ronnie Tung Ping Poon; Wai Kay Seto; James Fung; Ivan Fan Ngai Hung; Man Fung Yuen
Journal:  Hepatology       Date:  2011-07-21       Impact factor: 17.425

6.  Occult and previous hepatitis B virus infection are not associated with hepatocellular carcinoma in United States patients with chronic hepatitis C.

Authors:  Anna S Lok; James E Everhart; Adrian M Di Bisceglie; Hae-Young Kim; Munira Hussain; Timothy R Morgan
Journal:  Hepatology       Date:  2011-08       Impact factor: 17.425

7.  Molecular cloning of the human hepatitis C virus genome from Japanese patients with non-A, non-B hepatitis.

Authors:  N Kato; M Hijikata; Y Ootsuyama; M Nakagawa; S Ohkoshi; T Sugimura; K Shimotohno
Journal:  Proc Natl Acad Sci U S A       Date:  1990-12       Impact factor: 11.205

8.  Hepatitis C-related hepatocellular carcinoma in the United States: influence of ethnic status.

Authors:  Adrian M Di Bisceglie; Andre C Lyra; Myron Schwartz; Rajender K Reddy; Paul Martin; Gregory Gores; Anna S F Lok; Khozema B Hussain; Robert Gish; David H Van Thiel; Zobair Younossi; Myron Tong; Tarek Hassanein; Luis Balart; Jacquelyn Fleckenstein; Stephen Flamm; Andres Blei; Alex S Befeler
Journal:  Am J Gastroenterol       Date:  2003-09       Impact factor: 10.864

9.  Diabetes increases the risk of hepatocellular carcinoma in the United States: a population based case control study.

Authors:  J A Davila; R O Morgan; Y Shaib; K A McGlynn; H B El-Serag
Journal:  Gut       Date:  2005-04       Impact factor: 23.059

10.  The impact of immigration on the increasing incidence of hepatocellular carcinoma in the United States.

Authors:  K Kulkarni; E Barcak; H El-Serag; R Goodgame
Journal:  Aliment Pharmacol Ther       Date:  2004-08-15       Impact factor: 8.171

View more
  2 in total

Review 1.  SEER cancer registry biospecimen research: yesterday and tomorrow.

Authors:  Sean F Altekruse; Gabriel E Rosenfeld; Danielle M Carrick; Emilee J Pressman; Sheri D Schully; Leah E Mechanic; Kathleen A Cronin; Brenda Y Hernandez; Charles F Lynch; Wendy Cozen; Muin J Khoury; Lynne T Penberthy
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2014-12       Impact factor: 4.254

2.  Occult HCV infection in liver transplanted patients: frequency and consequences.

Authors:  Zeinab M Saad; Wael Abd El Ghany; Rofida Khalifa; Aliaa Higazi; Mostafa Al-Shazly; Mohamed Said; Hesham Keryakos
Journal:  Clin Exp Hepatol       Date:  2022-04-05
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.